Form 4: Mineralys CMO Sells Shares After Option Exercise

Mineralys Therapeutics' Chief Medical Officer, David Malcom Rodman, sold shares of common stock in January 2026 following the exercise of stock options, pursuant to a pre-arranged 10b5-1 trading plan.

Summary

• David Malcom Rodman, Chief Medical Officer of Mineralys Therapeutics, Inc. (MLYS), engaged in multiple transactions involving the company's common stock in January 2026.
• On January 9, 2026, Rodman exercised stock options to acquire 2,170 shares at an exercise price of $16.00 per share.
• Immediately following, he sold 2,170 shares of common stock at a price of $33.27 per share.
• On January 12, 2026, Rodman exercised stock options to acquire 6,348 shares at an exercise price of $1.08 per share.
• Concurrently, he sold 6,348 shares of common stock at a weighted-average price of $32.3162 per share, with individual sales ranging from $32.01 to $32.93.
• All reported transactions were conducted under a Rule 10b5-1 trading plan adopted on October 6, 2025.
• Following these transactions, Rodman's direct beneficial ownership of common stock remained at 61,804 shares.
• His remaining beneficially owned stock options are 28,218 (from the $16 exercise price grant) and 38,092 (from the $1.08 exercise price grant).

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While insider selling can be seen negatively, the transactions were pre-planned under a 10b5-1 plan, mitigating concerns about opportunistic selling. The officer realized significant gains from option exercises, which is a positive for individual compensation but not directly for the company's operational performance.

Positives

• The exercise of stock options indicates the officer is realizing value from previously granted equity compensation.
• The sale prices of $33.27 and a weighted-average of $32.3162 are significantly higher than the exercise prices of $16.00 and $1.08, indicating a substantial profit for the officer.
• Transactions were conducted under a Rule 10b5-1 trading plan, suggesting pre-planned activity rather than a reaction to new, negative information.

Negatives

• Insider selling, even if pre-planned, can sometimes be perceived negatively by the market as it reduces the officer's direct equity stake.

Future Outlook

No future outlook or guidance provided.

Industry Context

This filing is a routine insider transaction and does not provide information to analyze broader industry trends or competitors.

Stakeholder Impact

• Shareholders: May view the insider selling with slight caution, though the 10b5-1 plan mitigates immediate concerns. The officer's beneficial ownership of common stock remained stable after the sales.
• Employees: No direct impact mentioned.
• Customers/Suppliers/Creditors: No direct impact mentioned.

Key Dates

Recommendation

The filing details routine insider transactions by the Chief Medical Officer, executed under a pre-established 10b5-1 trading plan. While the officer realized significant gains from option exercises, these sales do not reflect new operational or strategic information about Mineralys Therapeutics. Investors should consider these transactions as part of a planned compensation strategy rather than a signal of future company performance. The filing itself provides no new fundamental data to warrant a change in investment thesis, thus a 'hold' recommendation is appropriate.

Keywords

Mineralys Therapeutics, MLYS, Form 4, Insider Trading, Stock Options, Equity Compensation, Rule 10b5-1, Chief Medical Officer, David Malcom Rodman, Share Sale